{"prompt": "['Sponsor: APGD', 'ISN/Protocol 7465-CL-0301', 'EudraCT number 2017-003344-21', '- CONFIDENTIAL -', 'If required by local regulations, the investigator shall make accurate and adequate written', 'progress reports to the IEC/IRB at appropriate intervals, not exceeding 1 year. The', 'investigator shall make an accurate and adequate final report to the IRB/IEC within 90 days', 'after the close-out visit or termination of the study.', '8.2.2', 'Ethical Conduct of the Study', 'The study will be conducted in accordance with the protocol, ICH guidelines, applicable', 'regulations and guidelines governing clinical study conduct and the ethical principles that', 'have their origin in the Declaration of Helsinki.', '8.2.3', 'Informed Consent of Subjects', '8.2.3.1 Subject Information and Consent', 'The investigator or his/her representative will explain the nature of the study to the subject or', 'his/her guardian or legal representative, and answer all questions regarding this study. Prior', 'to any study-related screening procedures being performed on the subject, the informed', 'consent statement will be reviewed and signed (place a personal seal, if applicable) and dated', 'by the subject or his/her guardian or legal representative, the person who administered the', 'informed consent and any other signatories according to local requirements. A copy of the', 'signed or sealed informed consent form will be given to the subject and the original will be', \"placed in the subject's medical record. An entry must also be made in the subject's dated\", 'source documents to confirm that informed consent was obtained prior to any study-related', 'procedures and that the subject received a signed copy.', 'The signed consent forms will be retained by the investigator and made available (for review', 'only) to the study monitor and auditor regulatory authorities and other applicable individuals', 'upon request.', \"8.2.3.2 Supply of New and Important Information Influencing the Subject's Consent\", 'and Revision of the Written Information', '1.', 'The investigator or his/her representative will immediately inform the subject orally', \"whenever new information becomes available that may be relevant to the subject's\", \"consent or may influence the subject's willingness to continue to participate in the\", 'study (e.g., report of serious drug adverse drug reaction). The communication must be', \"documented in the subject's medical records and whether the subject is willing to\", 'remain in the study or not must be confirmed and documented.', '2. The investigator must update their ICF and submit it for approval to the IRB/IEC. The', 'investigator or his/her representative must obtain written informed consent from the', 'subject on all updated ICFs throughout their participation in the study. The', 'investigator or his/her designee must reconsent subjects with the updated ICF even if', 'relevant information was provided orally. The investigator or his/her representative', 'who obtained the written informed consent and the subject should sign and date the', 'informed consent form (place a personal seal, if applicable). A copy of the signed or', 'sealed informed consent form will be given to the subject and the original will be', '14 Sep 2020', 'Astellas', 'Page 95 of 143', 'Version 4.0 Incorporating Substantial Amendment 3']['Sponsor: APGD', 'ISN/Protocol 7465-CL-0301', 'EudraCT number 2017-003344-21', '- CONFIDENTIAL -', \"placed in the subject's medical record. An entry must be made in the subject's records\", 'documenting the re-consent process.', '8.2.4', 'Subject Confidentiality and Privacy', 'Individual subject medical information obtained as a result of this study is considered', 'confidential and disclosure to third parties is prohibited. Such medical information may be', \"given only after approval of the subject to the subject's physician or to other appropriate\", \"medical personnel responsible for the subject's well-being.\", 'The sponsor shall not disclose any confidential information on subjects obtained during the', 'performance of their duties in the clinical study without justifiable reasons.', 'Even though any individuals involved in the study, including the study monitors and auditors,', \"may get to know matters related to subject's privacy due to direct access to source documents,\", 'or from other sources, they may not leak the content to third parties.', \"The sponsor affirms the subject's right to protection against invasion of privacy. Only a\", 'subject identification number and/or initials will identify subject data retrieved by the', \"sponsor. However, the sponsor requires the investigator to permit the sponsor, sponsor's\", 'representative(s), the IRB/IEC and when necessary, representatives of the regulatory health', 'authorities to review and/or to copy any medical records relevant to the study.', 'The sponsor agrees to comply and process personal data in accordance with all applicable', 'privacy laws and regulations, including, without limitation, the Personal Information', 'Protection Law in Japan and Privacy laws in the US. If the services will involve the', 'collection or processing of personal data (as defined by applicable data protection legislation)', 'within the European Economic Area (EEA), then sponsor shall serve as the controller of such', 'data, as defined by the EU Data Protection Directive, and Investigator and/or third party shall', 'act only under the instructions of the sponsor in regard to personal data. If sponsor is not', 'based in the EEA, sponsor must appoint a third party to act as its local data protection', 'representative or arrange for a co-controller established in the EU for data protection', 'purposes in order to comply with the Directive.', '8.3', 'Administrative Matters', '8.3.1', 'Arrangement for Use of Information and Publication of the Clinical Study', 'Information concerning the study drug, patent applications, processes, unpublished scientific', \"data, the Investigator's Brochure and other pertinent information is confidential and remains\", 'the property of the sponsor. Details should be disclosed only to the persons involved in the', 'approval or conduct of the study. The investigator may use this information for the purpose', 'of the study only. It is understood by the investigator that the sponsor will use the', 'information obtained during the clinical study in connection with the development of the', 'drug and therefore may disclose it as required to other clinical investigators or to regulatory', 'agencies. In order to allow for the use of the information derived from this clinical study, the', 'investigator understands that he/she has an obligation to provide the sponsor with all data', 'obtained during the study.', '14 Sep 2020', 'Astellas', 'Page 96 of 143', 'Version 4.0 Incorporating Substantial Amendment 3']\n\n###\n\n", "completion": "END"}